Importance and Management of Non-High Density Lipoprotein Cholesterol in Dyslipidemia Treatment (JACC Asia April 2026)-Article: Importance and Management of Non-High Density Lipoprotein Cholesterol in Dyslipidemia Treatment

Article: Importance and Management of Non-High Density Lipoprotein Cholesterol in Dyslipidemia Treatment

Pdf Summary

This JACC: Asia expert consensus addresses persistent “residual” cardiovascular risk in Asian and Asia-Pacific populations despite achieving LDL-cholesterol (LDL-C) goals with statins. The authors emphasize that atherogenic risk is also driven by triglyceride-rich and other ApoB-containing lipoproteins (eg, VLDL, IDL, remnant particles, and lipoprotein[a]), which are common in atherogenic dyslipidemia associated with obesity, metabolic syndrome, and type 2 diabetes—conditions increasingly prevalent in the Asia-Pacific region.<br /><br />Using a modified Delphi process, 11 experts from 10 Asia-Pacific countries agreed on 18 statements highlighting non–HDL-cholesterol (non–HDL-C) as a practical, robust marker of total atherogenic cholesterol burden. Non–HDL-C is easily calculated from a standard lipid panel (total cholesterol minus HDL-C), requires no added cost, can be assessed in nonfasting samples, and is less prone to error than calculated LDL-C when triglycerides are elevated or LDL-C is very low. Evidence from meta-analyses and cohort studies (including Asia-Pacific data) suggests non–HDL-C predicts ASCVD events and mortality better than LDL-C and helps identify residual risk when LDL-C appears controlled.<br /><br />The panel recommends routinely evaluating non–HDL-C in patients with atherogenic dyslipidemia and using a non–HDL-C goal approximately 30 mg/dL (0.8 mmol/L) above the desired LDL-C target, consistent with many guidelines. Management should start by optimizing LDL-C–lowering therapy (statins and, where available/affordable, ezetimibe, bile acid sequestrants, bempedoic acid, or PCSK9 inhibitors). If LDL-C is at goal but non–HDL-C remains elevated, therapies targeting triglyceride-rich lipoproteins—particularly fibrates and selected omega-3 fatty acids—may reduce events; benefits are strongest in trials using high-dose pure EPA. Fenofibrate is preferred for statin combination due to lower myopathy risk than gemfibrozil and may also reduce diabetic microvascular complications (notably retinopathy). The document complements, rather than replaces, local Asia-Pacific guidelines and calls for broader implementation of non–HDL-C targeting.

Keywords

residual cardiovascular risk

Asia-Pacific dyslipidemia

non-HDL cholesterol

ApoB-containing lipoproteins

triglyceride-rich lipoproteins

atherogenic dyslipidemia

metabolic syndrome

type 2 diabetes

LDL-C goal with statins

high-dose EPA omega-3